Severe depression: Is there a best approach?

CNS Drugs

Volumn 15, Issue 10, 2001, Pages 765-776

  Sonawalla, Shamsah B ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZAMIDE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CLOZAPINE; DOPAMINE; LITHIUM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; THIOXANTHENE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

BEHAVIOR THERAPY; COGNITION; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIAGNOSTIC IMAGING; DISEASE SEVERITY; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS;

EID: 0035169180     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115100-00003     Document Type: Review

References (105)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Study
2. The economic burden of depression in 1990
3. Treatment of severe depression
4. The global burden of disease in 1990: Final results and their sensitivity to alternative epidemiological perspectives. Distant rates, age weights, and disability weights
5. The functioning and well-being of depressed patients: Results from the medical outcomes study
6. Suicide and psychiatric diagnosis
7. Characteristics of treatment resistant depression
8. Is severe depression a separate indication?
9. Comparative validity of two measures of psychomotor function in patients with severe depression
10. Psychomotor change as a feature of depressive disorders: An historical overview
11. A new depression scale designed to be sensitive to change
12. A rating scale for depression
13. An inventory for measuring depression
14. Quantitative ratings of depressive states
15. National Institute of Mental Health treatment of depression collaborative research program: General effectiveness of treatments
16. Controversies in the diagnosis and treatment of severe depression
17. Algorithms for the treatment of subtypes of unipolar major depression
18. Major depressive subtypes and treatment response
19. Paroxetine in the treatment of melancholia and severe depression
20. Distinguishing psychotic and non-psychotic melancholia
21. Family functioning in severe depressive disorders
22. Coexisting dysregulations of both the sympathoadrenal system and hypothalamic-pituitary-adrenal-axis in melancholia
23. Severity of depression and hypothalamic-pituitary-adrenal axis dysregulation: Identification of contributing factors
24. Relationships of the dexamethasone suppression test to clinical severity and degree of melancholia
25. A study on the blunted natural killer cell activity in severely depressed patients
26. Impaired lymphocyte function in depressive illness
27. Impaired lymphocyte stimulation by mitogens in severely depressed patients: A complex interface with HPA-axis hyperfunction, noradrenergic activity and the ageing process
28. Natural killer cell activity in depressive illness: Preliminary report
29. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression
30. Unrecognized physical illness prompting psychiatric admission: A prospective study
31. Assessment of severe depressive disorders
32. Recovery and major depression: Factors associated with twelve-month outcome
33. Anxiety and depression in a community sample: The influence of comorbidity on social functioning
34. Depression and panic attacks: The significance of overlap as reflected in follow-up and family study data
35. Anxious depressions: Clinical, family history, and naturalistic outcome - Comparisons with panic and major depressive disorders
36. Social functioning in patients with anxious depression versus major depressive disorder
37. A functional anatomical study of unipolar depression
38. Reduction of prefrontal cortex glucose metabolism common to three types of depression
39. Changes in regional brain activity in major depression after successful treatment with antidepressant drugs
40. Increased cerebral blood flow in depressed patients responding to electroconvulsive therapy
41. Single photon emission tomography with 99mTc-exametazime in major depression and the pattern of brain activity underlying the psychotic/neurotic continuum
42. Evaluation of brain perfusion with technetium-99m bicisate single-photon emission tomography in patients with depressive disorder before and after treatment
43. Regional cerebral blood flow in unipolar depression measured with Tc-99m-HMPAO single photon emission computed tomography: Negative findings
44. Subcortical hyperintensities on magnetic resonance imaging: Clinical correlates and prognostic significance in patients with severe depression
45. Quantitative cerebral anatomy in depression: A controlled magnetic resonance imaging study
46. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine
47. Factors associated with 1-year outcome of major depression in the community
48. Does the duration of illness before treatment affect the time taken to recover on treatment in severely depressed women?
49. Life events, social support and marital relationships in the outcome of severe depression
50. Do psychosocial factors influence outcome in severely depressed female psychiatric in-patients?
51. Outcome definitions and predictors in depression
52. The treatment of severe depression: Is there an efficacy gap between SSRI and TCA antidepressant generations?
53. The enduring psychosocial consequences of mania and depression
54. Definition and epidemiology of treatment-resistant depression
55. La depression resistante
56. Citalopram: Clinical effect profile in comparison with clomipramine: A controlled multicenter study
57. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study
58. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia
59. Severity of depression and response to fluoxetine
60. Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs
61. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease
62. Fluvoxamine and clomipramine in depressed hospitalised patients: Results from a randomised, double-blind study
63. Optimal dose regimen for paroxetine
64. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression
65. The pharmacologic profile of mirtazapine
66. Efficacy of antidepressants in the treatment of severe depression: The place of mirtazapine
67. Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder
68. Effectiveness of venlafaxthe in patients hospitalized for major depression and melancholia
69. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
70. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression
71. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes
72. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression
73. A multicenter doubleblind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate to severe depression
74. A multicenter evaluation of buproprion versus placebo in hospitalized depressed patients
75. Reboxetine: A doubleblind comparison with fluoxetine in major depressive disorder
76. Moclobemide and tricyclic antidepressants in severe depression: Meta-analysis and prospective studies
77. A preliminary, open study of the combination of fluoxetine and desipramine treatment of major depression
78. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: Preliminary report
79. Lithium augmentation in antidepressant-resistant patients: A quantitative analysis
80. Monoamine dysfunction and the pathophysiology and treatment of depression
81. Lithium and desipramine versus desipramine alone in the treatment of severe major depression: A preliminary study
82. Treatment-resistant mood disorders
83. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression
84. Is a cut-off score a suitable measure of treatment outcome in short-term trials in depression? A methodological meta-analysis
85. Uptake inhibition of biogenic amines by newer antidepressant drugs: Relevance to the dopamine hypothesis of depression
86. Role of the dopaminergic system in depression
87. Dopamine receptors and the dopamine hypothesis of schizophrenia
88. Major tranquillisers used as antidepressants
89. Diagnosis and treatment of psychotic (delusional) depression
90. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders
91. Novel strategies for treatment-resistant depression
92. Cognitive-behavioral therapy of severe unipolar depression
93. Severity of depression and response to cognitive behavior therapy
94. Full and abbreviated courses of maintenance electroconvulsive therapy
95. Electroconvulsive therapy for severe depressive disorders
96. Potential drug-ECT interactions
97. Subjective side-effects during electro-convulsive therapy
98. Headache and electro-convulsive therapy
99. Effects of unilateral-nondominant vs bilateral ECT on memory and depression: A preliminary report